Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRK-950 + Ramucirumab + Paclitaxel in Gastric Cancer
NCT06038578Phase 2Recruiting
- Sponsor
- Toray Industries
- Start
- Oct 2023
- Primary completion
- Oct 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of TRK-950 in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Toray Industries. Primary endpoint: Progression-Free Survival at 24 months. Started Oct 2023; status: recruiting.
02
Drugs
TRK-950
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06038578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06038578.